華仁藥業(300110.SZ):全資子公司鹽酸去氧腎上腺素原料藥獲得上市申請批準通知書
格隆匯3月19日丨華仁藥業(300110.SZ)公佈,近日,華仁藥業股份有限公司全資子公司安徽恆星製藥有限公司(簡稱“安徽恆星製藥”)收到國家藥品監督管理局覈準簽發的“鹽酸去氧腎上腺素”《化學原料藥上市申請批準通知書》(通知書編號:2025YS00221)。
鹽酸去氧腎上腺素是一種α-1腎上腺素能受體激動劑,與血管平滑肌細胞上的α-1腎上腺素能受體相互作用導致細胞活化並導致血管收縮,適用於治療臨牀上由於麻醉下血管擴張所致的低血壓。根據藥智網統計數據,2023年鹽酸去氧腎上腺素原料藥國內用量爲0.83噸。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.